|
Market Closed -
Other stock markets
|
Pre-market 14:06:35 | |||
| 9.580 USD | +2.57% |
|
9.605 | +0.26% |
Company Valuation: BioCryst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,492 | 2,140 | 1,227 | 1,558 | 1,642 | 2,435 | - | - |
| Change | - | -14.12% | -42.68% | 26.97% | 5.43% | 48.27% | - | - |
| Enterprise Value (EV) 1 | 2,124 | 2,140 | 1,654 | 2,065 | 1,642 | 2,516 | 2,254 | 1,809 |
| Change | - | 0.77% | -22.74% | 24.91% | -20.49% | 53.19% | -10.4% | -19.74% |
| P/E | -13.4x | -8.63x | -5.08x | -17.5x | 6.45x | -3.72x | 15.3x | 13x |
| PBR | -23.9x | -7.32x | -2.71x | -3.27x | - | -7.84x | -210x | 5.19x |
| PEG | - | -0.3x | 0.5x | 0.3x | -0x | 0x | -0x | 0.7x |
| Capitalization / Revenue | 15.9x | 7.9x | 3.7x | 3.46x | 1.88x | 3.64x | 3.35x | 2.81x |
| EV / Revenue | 13.5x | 7.9x | 4.99x | 4.58x | 1.88x | 3.76x | 3.1x | 2.09x |
| EV / EBITDA | -12x | -14.6x | -16.2x | -1,592x | 4.8x | -10.1x | 11.7x | 4.22x |
| EV / EBIT | -12x | -14.4x | -15.9x | -812x | 4.82x | -4.3x | 11.3x | 7.27x |
| EV / FCF | -14.7x | -13.1x | -17x | -38.9x | 4.76x | -104x | 9.39x | 5.78x |
| FCF Yield | -6.81% | -7.63% | -5.88% | -2.57% | 21% | -0.96% | 10.7% | 17.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 | -2.578 | 0.6269 | 0.7378 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 157.2 | 270.8 | 331.4 | 450.7 | 874.8 | 669.4 | 726.2 | 865.3 |
| EBITDA 1 | -176.9 | -147 | -102.1 | -1.297 | 342.4 | -248.1 | 192.6 | 428.3 |
| EBIT 1 | -177.7 | -148.4 | -103.7 | -2.543 | 341 | -585.5 | 198.8 | 248.7 |
| Net income 1 | -184.1 | -247.1 | -226.5 | -88.88 | 263.9 | -641.1 | 140.9 | 193.6 |
| Net Debt 1 | -368.3 | - | 426.7 | 507.7 | - | 80.91 | -180.6 | -625.6 |
| Reference price 2 | 13.850 | 11.480 | 5.990 | 7.520 | 7.800 | 9.580 | 9.580 | 9.580 |
| Nbr of stocks (in thousands) | 179,936 | 186,424 | 204,809 | 207,133 | 210,543 | 254,163 | - | - |
| Announcement Date | 2/23/22 A | 2/21/23 A | 2/26/24 A | 2/24/25 A | 2/26/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.72x | 3.76x | -10.14x | -.--% | 2.43B | |
| 33.11x | 8.21x | 25.31x | 0.04% | 56.19B | |
| 20.62x | 6.35x | 13.89x | 1.54% | 54.83B | |
| -18.25x | 4.33x | -7.59x | -.--% | 23.04B | |
| -41x | 13.02x | -38.35x | -.--% | 22.7B | |
| 25.46x | 4.98x | 13.19x | -.--% | 20.23B | |
| 24.92x | 4.83x | 15.71x | -.--% | 17.83B | |
| -786.44x | 37.38x | -4208.26x | -.--% | 15.65B | |
| 45.88x | 18.59x | 47.88x | 0.08% | 15.24B | |
| 17.56x | 5.09x | 11.87x | -.--% | 14.03B | |
| Average | -68.19x | 10.65x | -413.65x | 0.17% | 24.22B | |
| Weighted average by Cap. | -36.23x | 9.67x | -261.44x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BCRX Stock
- Valuation BioCryst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
